Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

5.0%

2 terminated/withdrawn out of 40 trials

Success Rate

88.2%

+1.7% vs industry average

Late-Stage Pipeline

33%

13 trials in Phase 3/4

Results Transparency

0%

0 of 15 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
11(44.0%)
Phase 3
10(40.0%)
Phase 4
3(12.0%)
Phase 1
1(4.0%)
25Total
N/A(11)
Phase 3(10)
Phase 4(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (40)

Showing 20 of 40 trials
NCT05139329Not Yet Recruiting

The ORCHESTRATE-Myocarditis Registry

Role: collaborator

NCT04577859Not ApplicableActive Not Recruiting

Esophageal Protection Study: A Multicenter Study

Role: collaborator

NCT06488820Terminated

Safety and Efficacy of Pulsed-field Ablation for Atrial Fibrillation in High Versus Low-volume Ablation Centers (SAFFICIENT)

Role: lead

NCT06878924Not Yet Recruiting

Safety and Efficacy of Pulmonary Vein Isolation Using Pulsed-field Ablation (PFA) Combined with Either PFA-based Left Atrial Posterior Wall Isolation or Vein of Marshall Ethanol Ablation in Patients with Persistent Atrial Fibrillation

Role: lead

NCT04037397Phase 3Completed

First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment (RAAFT-3)

Role: collaborator

NCT05510167Not ApplicableUnknown

Post-ablation Alcohol Impacts Arrhythmia Recurrence, Quality of Life and Cognition in AF

Role: lead

NCT03502499Not ApplicableSuspended

Half-normal Saline in Idiopathic Left Ventricular Outflow Tract Arrhythmias Ablation

Role: lead

NCT03498586Not ApplicableCompleted

Half-normal Saline in Atrial Fibrillation Ablation

Role: lead

NCT04473807Phase 4Unknown

Feasibility and Safety of IV Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy

Role: collaborator

NCT04830774Not ApplicableUnknown

Natural History of COVID-19-Related Atrial Fibrillation

Role: lead

NCT03503253Not ApplicableUnknown

Transcatheter Leak Closure With Detachable Coils Following Incomplete Left Atrial Appendage Closure Procedures

Role: lead

NCT04726943Not ApplicableUnknown

RF Applications for Residual LAA Leaks

Role: lead

NCT04736524Unknown

Immune Response Following COVID-19 Vaccination

Role: lead

NCT04506229Unknown

Genetic Mechanisms Underlying SARS-CoV-2 Infection and the Impact of COVID-19 on Cognitive Function

Role: lead

NCT04372004Phase 1Unknown

Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19)

Role: lead

NCT04502017Phase 4Unknown

Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion

Role: lead

NCT04371926Not ApplicableWithdrawn

Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk

Role: lead

NCT04352764Unknown

ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings

Role: lead

NCT04115436Unknown

Association of Genetic Variants With Risk of Stroke in Patients With Atrial Fibrillation Off-anticoagulation

Role: lead

NCT02219841Unknown

Impact of Life-Style Modification On Ablation Outcome in Atrial Fibrillation

Role: lead